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The Journal of Immunology
Lack of Galactosylation Enhances the Pathogenic Activity of
IgG1 but Not IgG2a Anti-Erythrocyte Autoantibodies
Kiyoaki Ito,*,† Jun-ichi Furukawa,‡ Kazunori Yamada,*,† Ngoc Lan Tran,*
Yasuro Shinohara,‡ and Shozo Izui*
IgG bears asparagine-linked oligosaccharide side chains in the Fc region. Variations in their extent of galactosylation and sialylation
could modulate IgG Fc-dependent effector functions, and hence Ab activity. However, it has not yet been clarified whether the
pathogenic potential of IgG autoantibodies is consistently enhanced by the absence of galactose residues per se or the lack of ter-
minal sialylation, which is dependent on galactosylation. Moreover, it remains to be defined whether the increased pathogenicity of
agalactosylated IgG is related to activation of the complement pathway by mannose-binding lectin, as suggested by in vitro studies.
Using a murine model of autoimmune hemolytic anemia, we defined the contribution of galactosylation or sialylation to the path-
ogenic activity of IgG1 and IgG2a anti-erythrocyte class-switch variants of 34-3C monoclonal autoantibody. We generated their
degalactosylated or highly sialylated glycovariants and compared their pathogenic effects with those of highly galactosylated or
desialylated counterparts. Our results demonstrated that lack of galactosylation, but not sialylation, enhanced the pathogenic ac-
tivity of 34-3C IgG1, but not IgG2a autoantibodies. Moreover, analysis of in vivo complement activation and of the pathogenic
activity in mice deficient in C3 or IgG FcRs excluded the implication of mannose-binding lectin-mediated complement activation
in the enhanced pathogenic effect of agalactosylated IgG1 anti-erythrocyte autoantibodies. The Journal of Immunology, 2014, 192:
581–588.
T
he CH2 domain of the IgG Fc portion carries asparagine-
linked biantennary complex-type oligosaccharide side chains
(N-glycans), which have been shown to be essential for
Fc-dependent effector functions of IgG (1–3). These N-glycan
structures are highly heterogeneous in terms of galactosylation
and sialylation (4, 5). Most of them end with either two
N-acetylglucosamines (i.e., agalactosylated G0 glycoform), one ga-
lactose and one N-acetylglucosamine (G1), or two galactose
residues (G2), but a significant, although minor, fraction of ga-
lactosylated glycans bears one or two terminal sialic acids (S1 or
S2). It has been shown that the proportion of IgG lacking galac-
tose is significantly increased in patients with a variety of chronic
inflammatory diseases, most notably rheumatoid arthritis (4, 6–
10). Increased levels of agalactosylated IgG have been shown to
correlate with disease severity and also have prognostic value.
More significantly, improvement of rheumatoid arthritis after anti-
TNF therapy or during pregnancy was associated with decreases in
levels of agalactosylated IgG (11–16). Notably, an enhanced arthri-
togenic activity of galactosidase-treated anti-collagen Abs has
been reported in a murine model of collagen-induced arthritis (17).
In contrast, studies with degalactosylated human IgG1 mAbs ob-
tained through treatment with galactosidase failed to show enhanced
Fc-dependent effector functions, as compared with their wild-type
(WT) counterparts (18, 19). Moreover, studies on autoimmune-
prone MRL-Faslpr mice displaying the aberrant IgG galactosylation
(5, 20) revealed that increases of agalactosylated IgG occurred in-
dependently of disease activity (21). Thus, it has been unclear
whether the pathogenic potential of IgG autoantibodies is con-
sistently enhanced by the absence of galactosylation.
In addition, it remains to be defined what mechanism may lead
to a possible enhancement of pathogenic activity of agalactosylated
IgG. It has previously been suggested that agalactosylated IgGmight
more efficiently activate complement through the lectin pathway
as a result of interaction of mannose-binding lectin (MBL) with
N-acetylglucosamines exposed by the lack of galactosylation (22,
23). However, studies with anti-platelet monoclonal autoantibodies
showed a minor role for MBL-dependent complement activation but
a dominant one for IgG FcRs (FcgRs) in mediating the pathoge-
nicity of degalactosylated IgG Abs (23). Nevertheless, the inter-
pretation of these results was still tentative, because it has been
shown that complement plays a minimal role in the pathogenesis of
this model of immune thrombocytopenia (23, 24). Alternatively,
because of a decreased interaction of highly sialylated IgG with
FcgRs (25), it has been proposed that the enhanced pathogenicity of
agalactosylated IgG could be attributed to their inability to undergo
terminal sialylation, which is dependent on upstream galactosylation,
rather than the lack of galactosylation (23, 26). However, it should
be noted that the anti-inflammatory properties of highly sialylated
IgG remain a controversial issue (19, 27–30). Notably, a more
recent study reported that IgG galactosylation, but not sialylation,
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was associated with the improvement of disease activity during
pregnancy in patients with rheumatoid arthritis (16). Thus, it re-
mains to be clarified whether it is the level of galactosylation of
IgG autoantibodies per se or the level of terminal sialylation that
modulates their pathogenic potential.
To better define the contribution of galactosylation and sialylation
of N-glycans to the pathogenic potential of IgG autoantibodies, we
have used a murine model of autoimmune hemolytic anemia (AIHA)
induced by 34-3C IgG anti-RBC monoclonal autoantibodies, spe-
cific against erythrocyte Band 3 protein (31), established from
autoimmune-prone NZB mice (32, 33). The previous analysis of
IgG switch variants of 34-3C mAb demonstrated the remarkably
different pathogenic potential of four IgG subclasses, as a function
of their respective capacities to interact with different classes of
FcgR and to activate complement in vivo (33–35). Indeed, the
IgG2a subclass of 34-3C mAb, which activates three different
FcgRs (FcgRI, FcgRIII, and FcgRIV) and complement, displayed
the highest pathogenic activity, whereas its IgG1 variant capable
of activating only FcgRIII, but not complement, exhibited the
weakest pathogenic potential (33, 36, 37). In this study, we gen-
erated degalactosylated or highly sialylated variants of 34-3C
IgG1 and IgG2a mAbs, and compared their pathogenic potentials
with those of highly galactosylated or desialylated counterparts.
Our results demonstrated that the pathogenic activity of 34-3C
IgG1, but not IgG2a anti-RBC autoantibodies was enhanced after
degalactosylation, whereas the mere extent of sialylation had no
effect on pathogenic potential. Moreover, we observed that aga-
lactosylated IgG1 anti-RBC mAb failed to display complement
activation in vivo, thereby arguing against the contribution of MBL-
dependent complement activation to the enhanced pathogenic ac-
tivity of degalactosylated IgG1 anti-RBC mAb.
Materials and Methods
Mice
C57BL/6 (B6) mice deficient in FcR g-chains (i.e., lacking functional ex-
pression of FcgRI, FcgRIII, and FcgRIV involved in erythrophagocytosis)
were generated with B6-derived embryonic stem cells (38). C3-deficient mice,
generated by gene targeting in 129-derived embryonic stem cells (39), were
backcrossed for five generations on a B6 background, as described previ-
ously (33). B6 mice were purchased from the Jackson Laboratory (Bar Har-
bor, ME). Animal studies described in this report have been approved by the
Ethical Committee for Animal Experimentation of the University of Geneva.
Anti-RBC mAbs
Hybridoma-secreting 34-3C IgG2a anti-RBC mAb was established from
unmanipulated NZB mice (32). The generation of a 34-3C IgG1 class-
switch variant and a 34-3C IgG2a F243A mutant carrying phenylalanine
instead of alanine at position 243 in the CH2 domain was previously de-
scribed (33, 40). All the hybridoma and transfectoma cells were grown in
DMEM supplemented with 1% Ultroser HY (PALL Life Sciences, Cergy,
France), and IgG mAbs were purified from culture supernatants by protein
G column chromatography. The purity of IgG was .95%, as documented
by SDS/PAGE.
Experimental AIHA
AIHAwas induced by a single i.v. injection of purified anti-RBC mAb into
2- to 3-mo-old mice. The injection of mAb was controlled by assessing the
level of Ab opsonization of RBCs 24 h later using biotinylated rat anti-
mouse k-chain mAb (H139.52.1.5), followed by PE-conjugated streptavi-
din, as described previously (35). The deposition of C3 on RBCs was
determined with biotinylated goat anti-mouse C3 (Cappel Laboratories,
Durham, NC), followed by PE-conjugated streptavidin (33). Hematocrit
(Ht) values were determined after centrifugation of blood samples col-
lected into heparinized microhematocrit tubes.
Degalactosylation and desialylation of IgG mAb
34-3C IgG1 and IgG2a mAbs in 0.05 M sodium phosphate buffer (pH 6.0)
were incubated with b1,4-galactosidase (15 mU for 1 mg IgG) cloned from
Streptococcus pneumoniae (EMD Chemicals, San Diego, CA) at 37˚C for
48 h. 34-3C IgG2a F243A mutant in 0.05 M acetate buffer (pH 5.5) was
incubated with a2,3/a2,6-neuraminidase (200 U for 1 mg IgG) cloned from
Clostridium perfringens (New England Biolabs, Herts, U.K.) at 37˚C for
48 h. Then galactosidase- or neuraminidase-treated IgG was dialyzed against
PBS and purified by protein G column chromatography. As a control, mAbs
were treated similarly in the absence of galactosidase or neuraminidase.
Sambucus nigra agglutinin lectin affinity chromatography
To enrich sialylated 34-3C IgG2a F243A, we used Sambucus nigra ag-
glutinin (SNA) lectin fractionation as described by Kaneko et al. (25). In
brief, 30 mg 34-3C IgG2a F243Awas dialyzed against TBS containing 0.1
mM CaCl2 and applied to 2 ml of an agarose-bound SNA lectin column
(Vector Laboratories, Burlingame, CA). The flow-through fraction was
collected by washing the column with TBS containing 0.1 mM CaCl2.
Then 34-3C IgG2a F243A bound to SNA lectin column was eluted in two
steps using 0.5 M lactose in TBS, followed by 0.5 M lactose in 0.2 M
acetic acid. All fractions were dialyzed against PBS.
Analysis of oligosaccharide structures
Purification of N-glycans from different IgG mAbs was performed based on
chemoselective glycoblotting technique, as described previously (40–42). In
brief, IgG samples were reductively alkylated under the presence of detergent
and then digested with trypsin and peptide N-glycosidase F (Roche Diag-
nostics, Penzberg, Germany) (43). The digested samples were mixed with
a novel hydrazide-functionalized glycoblotting polymer (42), and sialic acids
were methyl-esterified to render sialylated oligosaccharides chemically
equivalent to neutral oligosaccharides (44). The IgG oligosaccharides recov-
ered as derivatives of Na-([amino-oxy]acetyl)tryptophanylarginine methyl
ester were subjected to MALDI-TOF mass spectrometry (MALDI-TOF
MS) using an Ultraflex II mass spectrometer (Bruker Daltonik, Bremen,
Germany) controlled by the FlexControl 3.0 software package. The an-
alytical procedure was proved to be reproducible with a coefficient of
variation ,15% by analysis of N-linked oligosaccharides prepared from
normal human serum and from human IgG (42). Some glycan signals
were further analyzed by TOF/TOF as described previously (45). Esti-
mation of oligosaccharide structures was obtained by input of peak masses
into the GlycoMod Tool (http://au.expasy.org/tools/glycomod/) or Glyco-
Suite Tool (http://www.unicarbkb.org/query) and by referring literatures
describing the N-glycan of IgG (25, 46).
Statistical analysis
Unpaired comparison for Ht values was analyzed by Student t test. The
p values ,5% were considered significant.
Results
Development of more severe anemia after injection of
degalactosylated 34-3C IgG1 glycovariant than WT 34-3C
IgG1 mAb
To determine the contribution of galactosylation of IgG anti-RBC
autoantibodies to the development of AIHA, a degalactosylated 34-
3C IgG1 anti-RBC glycovariant was generated. Because this mAb
was very poorly sialylated (40), we treated it directly with b1,4-
galactosidase in vitro without pretreatment with neuraminidase.
When the extent of degalactosylation was controlled by MALDI-
TOF MS analysis on N-glycans released from 34-3C IgG1, we
observed that .95% of galactose residues were successfully re-
moved after treatment with b1,4-galactosidase (Fig. 1, Table I).
Accordingly, the content of agalactosylated G0 glycoform amounted
to 96.4%, 2.2-fold higher than that of WT 34-3C IgG1. It should
be stressed that the nucleotide sequence analysis of the variable
regions of 34-3C mAb excluded the presence of potential
N-glycosylation sites in its Fab region (47).
The pathogenic potential of degalactosylated 34-3C IgG1 variant
was then compared with that of its more highly galactosylated WT
counterpart by assessing the development of AIHA in B6 mice. As
reported previously (33), a single injection of 500 mg 34-3C IgG1
anti-RBC mAbs resulted in transient decreases in Ht values peaking
on day 4 (Fig. 2A). However, we observed that the degalactosylated
34-3C IgG1 variant induced a more severe anemia than WT 34-
3C IgG1. Indeed, 4 d after the injection, mice injected with the
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degalactosylated variant displayed a mean Ht value (6 SD) of
23.8 6 2.4%, which was significantly lower than that observed
with its WT counterpart (33.0 6 0.7%; p , 0.0001).
No complement activation by agalactosylated 34-3C IgG1
variant
An increased pathogenic activity of degalactosylated 34-3C IgG1
variant could be a result of the possible activation of complement
pathway by MBL, as suggested by in vitro studies (22). However,
circulating RBCs of B6 mice injected with the degalactosylated
34-3C IgG1 variant displayed only marginal C3 deposits (Fig.
2B), as was the case of mice injected with the WT 34-3C IgG1
mAb, which is known not to activate complement efficiently (33).
Moreover, the pathogenic effect of degalactosylated 34-3C IgG1
variant remained unchanged in C32/2 B6 mice but was com-
pletely abrogated in B6 mice deficient in FcR g-chains lacking
FIGURE 1. Degalactosylation of N-glycans of 34-3C IgG1 and
IgG2a mAbs treated with b1,4-galactosidase. Structures of dif-
ferent nonsialylated and sialylated glycoforms are depicted in the
upper panel, with the numbers corresponding to the respective
peaks on MALDI-TOF MS profiles of N-glycans released from 34-
3C IgG1 and IgG2a mAbs treated or not with galactosidase. Peaks
1 and 2 correspond to G0 glycoforms without or with a fucose,
peaks 3 and 4 to G1 glycoforms without or with a fucose, peaks 5
and 6 to G2 glycoforms without or with a fucose, and peaks 7 and
8 to S1 glycoforms with a fucose. Note almost complete disap-
pearance of G1 and G2 glycoforms (peaks 3–6) in 34-3C IgG1 and
IgG2a treated with galactosidase. Black squares represent N-ace-
tylglucosamine; gray circles represent mannose; white circles rep-
resent galactose; white diamonds represent N-glycolylneuraminic
acid; dark gray triangles represent fucose. m/z, Mass-to-charge ratio.
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FcgRs (Fig. 2C). These data indicated the lack of contribution of
MBL-dependent activation of complement to the development of
AIHA induced by degalactosylated 34-3C IgG1 mAb.
No enhanced pathogenic activity by degalactosylated 34-3C
IgG2a glycovariant as compared with WT 34-3C IgG2a
We have previously shown that the IgG2a subclass of the 34-3C
anti-RBC mAb is far more potent in inducing anemia than its IgG1
variant, which is due to an engagement of multiple phagocytic
receptors (FcgRI, FcgRIII, FcgRIV, and complement receptors),
as compared with the engagement of FcgRIII alone in IgG1-
induced anemia (33, 36, 37, 48). Because 34-3C IgG2a mAb is
much more galactosylated than its IgG1 variant (Table I), we
determined whether the pathogenic effect of this highly potent
IgG2a subclass of 34-3C mAb could also be enhanced through
degalactosylation. MALDI-TOF MS analysis on N-glycans re-
leased from b1,4-galactosidase–treated 34-3C IgG2a confirmed an
efficient removal of galactose residues, as the content of aga-
lactosylated G0 glycoform amounted to 97.0%, 6.6-fold higher
than that of WT 34-3C IgG2a (Fig. 1, Table I). However, in
contrast with the 34-3C IgG1 subclass, degalactosylated 34-3C
IgG2a variant failed to induce more severe anemia than its more
highly galactosylated WT counterpart (Fig. 3A). Four days after
the injection, mice injected with the degalactosylated variant
displayed a mean Ht value (6 SD) of 24.0 6 3.2%, which was
indistinguishable from that observed with its WT counterpart
(24.0 6 1.2%).
Table I. Structural analysis of N-glycans purified from WT and





34-3C Galactosidase G0 G1 G2 S1 S2
IgG1 2 43.9 42.4 7.6 3.4 ,0.1
IgG1 + 96.4 0.2 0.4 2.0 0.1
IgG2a 2 14.3 65.9 15.1 0.3 ,0.1
IgG2a + 97.0 0.7 0.4 ,0.1 ,0.1
Results are expressed as relative abundance of nonsialylated (G0, G1, and G2)
and sialylated (S1 and S2) glycoforms among total oligosaccharides. Some of the
carbohydrate moieties could not be assigned to the glycoforms defined in Fig. 1.
However, these represent very minor fractions.
FIGURE 2. Development of more severe anemia without induction of
complement activation after injection of degalactosylated 34-3C IgG1
glycovariant than WT 34-3C IgG1 mAb. (A) A total of 500 mg dega-
lactosylated (s) or WT (d) 34-3C IgG1 was i.v. injected into B6 mice.
Results are expressed as mean Ht values (6 SD) of seven mice. (B) Flow
cytometric analysis of complement activation in vivo 24 h after an i.v.
injection of degalactosylated or WT 34-3C IgG1 (500 mg) or of control 34-
3C IgG2a (200 mg) anti-RBC mAb into B6 mice. RBCs were stained with
biotinylated goat anti-C3 Abs, followed by PE-conjugated streptavidin.
Shaded areas indicate the background staining obtained with untreated B6
mice. Note marginal C3 deposits on RBCs in mice injected with dega-
lactosylated 34-3C IgG1 variant, with levels as low as in those injected
with WT 34-3C IgG1, in contrast with a marked C3 deposition on RBCs in
those injected with 34-3C IgG2a mAb. (C) A total of 500 mg degalacto-
sylated 34-3C IgG1 variant was i.v. injected into WT, C32/2, and FcRg2/2
B6 mice. Ht values of individual mice determined 4 d after injection are
shown. Mean Ht values are indicated by horizontal lines. The normal
range of Ht values (mean 6 3 SD) of control B6 mice is represented as
shaded area.
FIGURE 3. No enhanced pathogenic activity by degalactosylated IgG2a
of 34-3C mAb, and efficient induction of anemia by various 34-3C IgG2a
F243A glycovariants independently of the extent of sialylation. (A) A total
of 100 mg degalactosylated (s) or WT (d) 34-3C IgG2a was i.v. injected
into B6 mice. Results are expressed as mean Ht values (6 SD) of seven
mice. (B) A total of 100 mg 34-3C IgG2a F243A of unfractionated (Total)
and fractionated preparations on SNA lectin column (SNA2 and SNA+), as
well as desialylated 34-3C IgG2a F243A mAb (asialyl), was injected i.v.
into B6 mice. Ht values of individual mice measured 4 d after injection of
different 34-3C IgG2a F243A glycovariants are shown. Mean Ht values are
indicated by horizontal lines. The normal range of Ht values (mean 6
3 SD) of control B6 mice is represented as shaded area.
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No modulation of pathogenicity by sialylation or desialylation
of 34-3C IgG2a F243A variant
In view of anti-inflammatory properties of IgG Abs enriched with
sialic acids (25–27), we have previously generated a more sialy-
lated 34-3C IgG2a F243A variant carrying phenylalanine instead
of alanine at position 243 in the CH2 domain, because this re-
placement has been shown to result in a remarkable increase in Fc
sialylation of human IgG3 (49, 50). Indeed, 34-3C IgG2a F243A
displayed a markedly increased content of sialylated glycoforms,
which accounted for ∼20% of total oligosaccharides, which con-
trasted with essentially absence of sialylated glycoforms (,1%) in
WT 34-3C IgG2a mAb (28). Despite these remarkable differences
in the content of sialylated glycoforms, the pathogenic activity of
34-3C IgG2a F243A mutant was comparable with that of WT
34-3C IgG2a. However, the significance of these results could be
dismissed by arguing that the content of sialylated glycoforms of
FIGURE 4. MALDI-TOF MS of N-glycans of different 34-3C
IgG2a F243A glycovariants. Structures of different nonsialylated
and sialylated glycoforms are depicted in the upper panel, with the
numbers corresponding to the respective peaks on MALDI-TOF
MS profiles of N-glycans released from 34-3C IgG2a F243A of
unfractionated and fractionated preparations on SNA lectin col-
umn chromatography, as well as desialylated 34-3C IgG2a F243A
mAb. Note marked increases in sialylated glycoforms (peaks 8–
10) in the SNA-bound fraction and their complete disappearance
in the desialylated 34-3C IgG2a F243A glycovariant. The glyco-
form corresponding to peak 7 is unusual, because it carries three
galactose residues. However, because both biantennary oligosac-
charide side chains end with galactose, this was classified as a G2
glycoform in this study. Closed squares represent N-acetylglu-
cosamine; gray circles represent mannose; open circles represent
galactose; open diamonds represent N-glycolylneuraminic acid;
dark gray diamonds represents N-acetylneuraminic acid; dark gray
triangles represent fucose.
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34-3C IgG2a F243A was not high enough to downmodulate the
Fc-dependent effector function, as more sialylated variants of 6A6
IgG1 and IgG2b anti-platelet mAbs displaying a lesser pathogenic
activity were prepared through fractionation on SNA lectin affinity
column (25).
Therefore, we further enriched sialylated species of 34-3C IgG2a
F243A through SNA lectin affinity column. In the end, 3.1% of
total 34-3C IgG2a F243A charged on SNA lectin column was
eluted using 0.5 M lactose. As documented by increases in S1 and
S2 glycoforms and concomitant decreases in the G2 glycoform
throughMALDI-TOFMS analysis, the fractionation on SNA lectin
column resulted in an enrichment of sialylated glycoforms of 34-3C
IgG2a F243A, which accounted for 50.7% of total oligosaccharides,
as compared with 16.7% in the unfractionated counterpart (Fig. 4,
Table II). When the content of sialic acid residues was expressed as
([% of S1] + 23 [% of S2]), the SNA-bound fraction had a 3.8-fold
higher value than the unfractionated 34-3C IgG2a F243A mAb
(70.7 versus 18.8). The observed sialic acid species in 34-3C IgG2a
F243A was mostly (.90%) N-glycolylneuraminic acid, rather than
N-acetylneuraminic acid (Fig. 4). A recovery of only 3.1% of 34-3C
IgG2a F243A and a remarkable enrichment of S2 glycoform
through SNA lectin affinity column chromatography is consistent
with the finding that the presence of two sialic acid residues in
N-glycans attached to the two H chains of an IgG molecule (either
because of the presence of one S2 glycoform or two S1 glycoforms)
is required for the efficient binding of sialylated IgG to SNA lectin
columns (51).
The pathogenic potential of the sialic acid–enriched SNA-bound
fraction of 34-3C IgG2a F243A was then compared with that of
the flow-through SNA-unbound fraction and of the unfractionated
counterpart. As shown in Fig. 3B, the extent of anemia provoked
by the injection of 100 mg of these three different preparations of
34-3C IgG2a F243A was similar (Ht values on day 4: unfractio-
nated, 32.4 6 1.5%; SNA unbound, 31.1 6 1.0%; SNA bound,
32.9 6 1.3%). Moreover, we generated desialylated 34-3C IgG2a
F243A variant through treatment with a2,3/a2,6-neuraminidase
in vitro. Structural analysis of N-glycans released from neuraminidase-
treated 34-3C IgG2a F243A confirmed a complete removal of ter-
minal sialic acid residues (Fig. 4, Table II). However, again, the
pathogenic effect of desialylated 34-3C IgG2a F243A (Ht values
on day 4: 32.3 6 2.2%) was indistinguishable from that of its
highly sialylated counterpart (Fig. 3B).
Discussion
This study was designed to more clearly define the respective con-
tributions of galactosylation and sialylation of N-glycans to the path-
ogenic potential of IgG autoantibodies in a murine model of AIHA.
Comparative analyses of degalactosylated or desialylated variants
versus their highly galactosylated or sialylated counterparts of
34-3C IgG1 and IgG2a anti-RBCmAbs revealed that the pathogenic
activity of IgG1, but not IgG2a anti-RBC autoantibodies was
modulated by galactosylation, but not sialylation. In addition, the
lack of any sign of increased complement activation in vivo by
degalactosylated 34-3C IgG1 variant clearly ruled out MBL-
mediated complement activation as a molecular mechanism re-
sponsible for the enhanced pathogenic effect of agalactosylated IgG.
Our demonstration that degalactosylated 34-3C IgG1 anti-RBC
mAb induced a more severe anemia than its WT counterpart shed
new light on the pathogenic potential of agalactosylated and asia-
lylated IgG. Because both WT and degalactosylated 34-3C IgG1
mAbs were hardly sialylated, it is clear that the difference in their
pathogenic activity cannot be attributed to differences in the extent
of terminal sialylation. Previous in vitro studies claimed that
agalactosylated IgG could enhance the activation of complement
through its interaction withMBL, thereby promoting its pathogenic
potential (22). However, we failed to see a significant activation of
complement by degalactosylated 34-3C IgG1 in vivo, as judged by
the lack of C3 deposits on RBCs in mice after injection. Moreover,
the absence of its pathogenic effect in mice deficient in FcgRs,
as well as no reduction of its pathogenicity in C32/2 mice, further
argue against the implication of MBL-dependent complement ac-
tivation in the pathogenic activity of agalactosylated 34-3C IgG1.
These data indicate a dominant role of FcgRs in promoting the
pathogenic effect of agalactosylated IgG Abs, in agreement with
observations made in the murine model of immune thrombocy-
topenia induced by 6A6 anti-platelet mAb (23).
It should be stressed, however, that we did not find any effect of
degalactosylation on the pathogenic activity of the IgG2a subclass
of 34-3C anti-RBC mAb. This indicates that the modulation of the
pathogenic potential of IgG autoantibodies through the extent of
galactosylation is dependent on the IgG subclass. Notably, the Fc-
dependent effector function of the IgG2a subclass is much more
efficient than that of the IgG1 subclass. Thus, it is likely that the
contribution of hypogalactosylation to the pathogenic potential of
IgG2a can be masked because of its potent engagement of multiple
phagocytic receptors (FcgRI, FcgRIII, FcgRIV, and complement
receptor) involved in AIHA, which contrasts with the involvement
of a single receptor, FcgRIII, by IgG1 (33, 36, 37). Our data could
explain the findings that no increased Fc-dependent effector func-
tions were observed after treatment with galactosidase of two dif-
ferent human IgG1 mAbs (18, 19), because the IgG1 subclass in
humans functionally corresponds to the IgG2a subclass in mice, as
it displays the highest Fc effector functions among the four dif-
ferent human IgG subclasses (52). This issue needs to be read-
dressed through the analysis of different human IgG subclasses.
We have previously shown that the 34-3C IgG2a F243A mutant,
which contained ∼20% sialylated glycovariants, efficiently inter-
acted with FcgRs and activated complement, and was as patho-
genic as barely sialylated WT Ab (28). However, sialylated 6A6
IgG1 and IgG2b antiplatelet glycovariants enriched through SNA
lectin affinity column chromatography were shown to be less
pathogenic as compared with their poorly sialylated counterparts
(25). Although detailed information on the yield and precise
content of sialylated glycoforms in these SNA-fractionated 6A6
Abs was not reported in that study, we assumed that the maintained
pathogenic activity of the unfractionated 34-3C IgG2a F243A could
be because of its possible lesser content of sialylated glycoforms
compared with SNA-fractionated 6A6. However, this analysis also
failed to show any difference in the pathogenic potential between
a 34-3C IgG2a F243A glycovariant containing more (∼50%) sia-
lylated glycoforms (obtained through SNA column fractionation)
and its enzymatically desialylated variant. These data rather argue
against the notion that sialylated IgG is less pathogenic because of
Table II. Structural analysis of N-glycans purified from different





F243A G0 G1 G2 S1 S2
Unfractionated 8.8 26.8 42.8 14.3 2.4
SNA unbound 8.4 27.0 45.3 12.8 1.8
SNA bound 5.5 20.6 22.4 30.7 20.0
Desialylated 9.5 29.5 54.7 ,0.1 ,0.1
Results are expressed as relative abundance of nonsialylated (G0, G1, and G2)
and sialylated (S1 and S2) glycoforms among total oligosaccharides. Some of the
carbohydrate moieties could not be assigned to the glycoforms defined in Fig. 4.
However, these represent very minor fractions.
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reduced binding to FcgRs, at least in our murine model of AIHA. In
this regard, it is worth noting that the ability of more highly sialy-
lated human IgG1 (obtained through lectin column chromatography
and containing 67% sialylated glycoforms) to interact with FcgRs
was comparable with that of a poorly (5%) sialylated variant (27).
At this moment, we cannot offer the straightforward explanation
why our results in the 34-3C anti-RBC mAb model contrast with
those obtained with the 6A6 anti-platelet mAb model, in which
the extent of sialylation, but not galactosylation, modulated patho-
genic potential (23, 25). However, it may be worth emphasizing that
the pathogenic mechanism responsible for the development of
thrombocytopenia induced by 6A6 IgG anti-platelet mAb appears
to be not totally identical to that for the development of AIHA
induced by 34-3C IgG anti-RBC mAb. First, the kinetics of de-
pletion of platelets and RBCs are markedly different because 6A6
anti-platelet mAb induced an efficient and rapid elimination of
platelets within 4 h, whereas the maximal drop of Ht was observed
only 4 d after injection of 34-3C anti-RBC mAb. Second, it has
been shown that blood monocytes were responsible for the elim-
ination of platelets in 6A6-induced immune thrombocytopenia (53),
whereas Kupffer cells in the liver are the major cell type involved in
RBC destruction in 34-3C–induced AIHA (32, 35). Third, com-
plement can play a substantial role in the development of AIHA
induced by complement-fixing IgG2a and IgG2b subclasses of 34-
3C (33), but only a little role, if any, in immune thrombocytopenia
induced by 6A6 IgG2b (23).
In conclusion, our study indicates that the extent of galactosylation
per se, but not galactosylation-dependent terminal sialylation, of
N-glycans attached to the Fc region contributes to the pathogenic
potential of IgG anti-RBC autoantibodies, but its effect is dependent
on the IgG subclass. Clearly, a more thorough analysis of Fc-
dependent effector functions of the different human IgG sub-
classes in relation to the extent of galactosylation would help
clarify the relevance of our observations to the human disease.
Moreover, a further better understanding of the interplay between
the structural characteristics of agalactosylated glycoforms of IgG
and their proinflammatory properties should provide useful guiding
principles for the engineering of mAbs for in vivo application.
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